Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China

Gao, Lan, Zhao, Fei-Li and Li, Shu-Chuen 2012, Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China, International journal of technology assessment in health care, vol. 28, no. 4, pp. 436-444, doi: 10.1017/S0266462312000608.

Attached Files
Name Description MIMEType Size Downloads

Title Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China
Author(s) Gao, LanORCID iD for Gao, Lan
Zhao, Fei-Li
Li, Shu-Chuen
Journal name International journal of technology assessment in health care
Volume number 28
Issue number 4
Start page 436
End page 444
Total pages 9
Publisher Cambridge University Press
Place of publication Cambridge, Eng.
Publication date 2012-10
ISSN 0266-4623
Keyword(s) cost-effectiveness
cost-utility analysis
type 2 diabetes mellitus
UKPDS Outcomes Model
Summary Objectives: The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population.

Methods: The validated UKPDS Outcomes Model was used to project life expectancy, quality adjusted life-years (QALYs), incidence of diabetes-related complication and cost of complications in patients receiving those regimens. Baseline cohort characteristics and treatment effects were derived from an Asian study. China-specific complication costs and utility score were taken from local studies. Patients’ outcomes were modeled for 30 years and incremental cost-effectiveness ratios were calculated for liraglutide compared with glimepiride from the healthcare system perspective. Both future costs and clinical benefits were discounted at 3 percent. Sensitivity analyses were performed.

Results: Over a period of 30 years, compared with glimepiride, liraglutide 1.8 mg was associated with improvements in life expectancy (0.1 year) and quality adjusted life-year (0.168 QALY), and a reduced incidence of diabetes-related complications leading to an incremental cost-effectiveness ratio per QALY gained versus glimepiride of CNY 25,6871 (DEC 2010, 1 USD = 6.6227 CNY).

Conclusions: Long-term projections indicated that liraglutide was associated with increased life expectancy, QALYs, and reduced complication incidences comparing with glimepiride. When the UK cost of liraglutide was discounted by 38 percent, liraglutide would be a cost-effective option in China from the healthcare system perspective using the 3X GDP/capita per QALY as the WTP threshold.
Language eng
DOI 10.1017/S0266462312000608
Field of Research 111799 Public Health and Health Services not elsewhere classified
1117 Public Health And Health Services
1402 Applied Economics
Socio Economic Objective 920104 Diabetes
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2012, Cambridge University Press
Persistent URL

Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 14 times in TR Web of Science
Scopus Citation Count Cited 15 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 280 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Wed, 12 Oct 2016, 10:58:53 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact